FOGHORN THERAPEUTICS INC (FHTX) Stock Price, Quote, News and Overview
NASDAQ:FHTX - Nasdaq - US3441741077 - Common Stock - Currency: USD
FHTX Quote, Performance and Key Statistics
5.23
-0.15 (-2.79%)
The current stock price of FHTX is 5.23 USD. In the past month the price increased by 19.41%. In the past year, price decreased by -12.54%.
FHTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FHTX
Company Profile
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2020-10-23. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The firm is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. The company is also developing FHD-909 a highly potent, allosteric and orally available small molecule.
Company Info
FOGHORN THERAPEUTICS INC
500 Technology Square, Suite 700
Cambridge MASSACHUSETTS 02139 US
CEO: Adrian Gottschalk
Employees: 116
Company Website: https://foghorntx.com/
Investor Relations: https://ir.foghorntx.com/
Phone: 16175863100
FOGHORN THERAPEUTICS INC / FHTX FAQ
What is the stock price of FOGHORN THERAPEUTICS INC today?
The current stock price of FHTX is 5.23 USD. The price decreased by -2.79% in the last trading session.
What is the ticker symbol for FOGHORN THERAPEUTICS INC stock?
The exchange symbol of FOGHORN THERAPEUTICS INC is FHTX and it is listed on the Nasdaq exchange.
On which exchange is FHTX stock listed?
FHTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FOGHORN THERAPEUTICS INC stock?
14 analysts have analysed FHTX and the average price target is 11.95 USD. This implies a price increase of 128.46% is expected in the next year compared to the current price of 5.23. Check the FOGHORN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FOGHORN THERAPEUTICS INC worth?
FOGHORN THERAPEUTICS INC (FHTX) has a market capitalization of 290.74M USD. This makes FHTX a Micro Cap stock.
How many employees does FOGHORN THERAPEUTICS INC have?
FOGHORN THERAPEUTICS INC (FHTX) currently has 116 employees.
What are the support and resistance levels for FOGHORN THERAPEUTICS INC (FHTX) stock?
FOGHORN THERAPEUTICS INC (FHTX) has a support level at 4.15 and a resistance level at 5.91. Check the full technical report for a detailed analysis of FHTX support and resistance levels.
Is FOGHORN THERAPEUTICS INC (FHTX) expected to grow?
The Revenue of FOGHORN THERAPEUTICS INC (FHTX) is expected to decline by -5.34% in the next year. Check the estimates tab for more information on the FHTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FOGHORN THERAPEUTICS INC (FHTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FHTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FHTX, evaluating the profitability, health, valuation and growth aspects
- FOGHORN THERAPEUTICS INC (FHTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FOGHORN THERAPEUTICS INC (FHTX) Sales and EPS estimates to see what analysts future expectations are.
- FOGHORN THERAPEUTICS INC (FHTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FOGHORN THERAPEUTICS INC (FHTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- FOGHORN THERAPEUTICS INC (FHTX) Stock Chart to make your own analysis
- FOGHORN THERAPEUTICS INC (FHTX) Latest news and press-releases to stay up to date.
Does FOGHORN THERAPEUTICS INC (FHTX) stock pay dividends?
FHTX does not pay a dividend.
When does FOGHORN THERAPEUTICS INC (FHTX) report earnings?
FOGHORN THERAPEUTICS INC (FHTX) will report earnings on 2025-03-06, after the market close.
What is the Price/Earnings (PE) ratio of FOGHORN THERAPEUTICS INC (FHTX)?
FOGHORN THERAPEUTICS INC (FHTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.92).
What is the Short Interest ratio of FOGHORN THERAPEUTICS INC (FHTX) stock?
The outstanding short interest for FOGHORN THERAPEUTICS INC (FHTX) is 2.04% of its float. Check the ownership tab for more information on the FHTX short interest.
FHTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to FHTX. When comparing the yearly performance of all stocks, FHTX is a bad performer in the overall market: 86.66% of all stocks are doing better.
FHTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FHTX. FHTX has a bad profitability rating. Also its financial health evaluation is rather negative.
FHTX Financial Highlights
Over the last trailing twelve months FHTX reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS increased by 21.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.58% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FHTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to FHTX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 28.89% and a revenue growth -5.34% for FHTX